Literature DB >> 26438504

Raltegravir Pharmacokinetics in Patients on Asunaprevir-Daclatasvir.

Aurélie Barrail-Tran1, Corine Vincent2, Valérie Furlan3, Isabelle Rosa4, Eric Rosenthal5, Antoine Cheret6, Jean-Michel Molina7, Anne-Marie Taburet8, Lionel Piroth9.   

Abstract

Raltegravir pharmacokinetics was studied in 20 patients included in the ANRS HC30 QUADRIH Study before and after addition of anti-hepatitis C virus (anti-HCV) quadritherapy, including pegylated-interferon-ribavirin and asunaprevir plus daclatasvir. Raltegravir pharmacokinetic parameters remained unchanged whether administered on or off anti-HCV therapy. In addition, concentrations of raltegravir, asunaprevir, and daclatasvir were not affected by liver cirrhosis. These data suggest that in human immunodeficiency virus (HIV)-HCV-coinfected patients, whether cirrhotic or not, asunaprevir and daclatasvir could be administered safely with raltegravir.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26438504      PMCID： PMC4649172          DOI： 10.1128/AAC.01603-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  9 in total

Review 1.  Drug interactions with new and investigational antiretrovirals.

Authors:  Kevin C Brown; Sunita Paul; Angela D M Kashuba
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

2.  High Cure Rate With 24 Weeks of Daclatasvir-Based Quadruple Therapy in Treatment-Experienced, Null-Responder Patients With HIV/Hepatitis C Virus Genotype 1/4 Coinfection: The ANRS HC30 QUADRIH Study.

Authors:  Lionel Piroth; Hubert Paniez; Anne Marie Taburet; Corine Vincent; Eric Rosenthal; Karine Lacombe; Eric Billaud; David Rey; David Zucman; François Bailly; Jean-Pierre Bronowicki; Mélanie Simony; Alpha Diallo; Jacques Izopet; Jean-Pierre Aboulker; Laurence Meyer; Jean-Michel Molina
Journal:  Clin Infect Dis       Date:  2015-05-14       Impact factor: 9.079

Review 3.  Clinical pharmacology profile of raltegravir, an HIV-1 integrase strand transfer inhibitor.

Authors:  Diana M Brainard; Larissa A Wenning; Julie A Stone; John A Wagner; Marian Iwamoto
Journal:  J Clin Pharmacol       Date:  2011-01-05       Impact factor: 3.126

4.  The pharmacokinetics of daclatasvir and asunaprevir administered in combination in studies in healthy subjects and patients infected with hepatitis C virus.

Authors:  Timothy Eley; Heather Sevinsky; Shu-Pang Huang; Bing He; Kurt Zhu; Hamza Kandoussi; David Gardiner; Dennis M Grasela; Richard Bertz; Marc Bifano
Journal:  Clin Drug Investig       Date:  2014-09       Impact factor: 2.859

5.  Daclatasvir + asunaprevir: first global approval.

Authors:  Raewyn M Poole
Journal:  Drugs       Date:  2014-09       Impact factor: 9.546

6.  Inter- and intra-patient variability of raltegravir pharmacokinetics in HIV-1-infected subjects.

Authors:  Dario Cattaneo; Cristina Gervasoni; Paola Meraviglia; Simona Landonio; Serena Fucile; Valeria Cozzi; Sara Baldelli; Michela Pellegrini; Massimo Galli; Emilio Clementi
Journal:  J Antimicrob Chemother       Date:  2011-11-29       Impact factor: 5.790

7.  Pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment experienced patients.

Authors:  Aurélie Barrail-Tran; Yazdan Yazdanpanah; Lauriane Goldwirt; Geneviève Chêne; Céline Colin; Christophe Piketty; Diane Bollens; Christine Katlama; Diane Descamps; Jean-Michel Molina; Catherine Fagard; Anne-Marie Taburet
Journal:  AIDS       Date:  2010-10-23       Impact factor: 4.177

8.  Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.

Authors:  M Iwamoto; L A Wenning; A S Petry; M Laethem; M De Smet; J T Kost; S A Merschman; K M Strohmaier; S Ramael; K C Lasseter; J A Stone; K M Gottesdiener; J A Wagner
Journal:  Clin Pharmacol Ther       Date:  2007-08-22       Impact factor: 6.875

9.  Pharmacokinetic study of raltegravir in HIV-infected patients with end-stage liver disease: the LIVERAL-ANRS 148 study.

Authors:  Caroline Barau; Joséphine Braun; Corine Vincent; Stéphanie Haim-Boukobza; Jean-Michel Molina; Patrick Miailhes; Isabelle Fournier; Jean-Pierre Aboulker; Daniel Vittecoq; Jean-Charles Duclos-Vallée; Anne-Marie Taburet; Elina Teicher
Journal:  Clin Infect Dis       Date:  2014-07-03       Impact factor: 9.079
  9 in total
  1 in total

Review 1.  A Review of Daclatasvir Drug-Drug Interactions.

Authors:  Tushar Garimella; Xiaoli You; Reena Wang; Shu-Pang Huang; Hamza Kandoussi; Marc Bifano; Richard Bertz; Timothy Eley
Journal:  Adv Ther       Date:  2016-09-23       Impact factor: 3.845
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.